Regeneron Pharmaceuticals Inc. buy Wolfe Research
Summary
This prediction ended on 16.11.25 with a price of €601.80. The prediction for Regeneron Pharmaceuticals Inc. disappointed with a performance of -18.72%. Dividends of €2.60 are taken into consideration when calculating the performance. Wolfe_Research has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.921% | -3.921% | 29.955% |
| iShares Core DAX® | 3.023% | 2.202% | 14.664% |
| iShares Nasdaq 100 | 3.561% | 1.325% | 31.410% |
| iShares Nikkei 225® | 6.618% | 5.707% | 49.420% |
| iShares S&P 500 | 2.635% | 1.008% | 25.116% |
Comments by Wolfe_Research for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Stopped prediction by Wolfe_Research for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
16.11.24
16.11.25
17.11.25

